SCHEMBL29960244

SCHEMBL29960244

OCc1c(Cl)cccc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TAAR1 Q96RJ0 2/20 0.41
GAA P10253 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 3/20 0.36
ADRA2A P08913 2/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
HTR1A P08908 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
MAOA P21397 1/20 0.36
ADRA1D P25100 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15569427 1.00 AKR1B1 (0.43) AKR1B1SMN1; SMN2TAAR1GAAALDH1A1
SCHEMBL110369 0.83 AKR1B1 (0.52) AKR1B1SMN1; SMN2TAAR1GAAALDH1A1
SCHEMBL1046232 0.83 GABRA1 (0.42) TAAR1GAAALDH1A1MAPK1GABRA1
SCHEMBL3411130 0.83 TAAR1 (0.43) AKR1B1SMN1; SMN2TAAR1GAAALDH1A1
SCHEMBL30831849 0.79 TAAR1 (0.43) AKR1B1SMN1; SMN2TAAR1GAAALDH1A1
SCHEMBL695878 0.79 TAAR1 (0.43) AKR1B1SMN1; SMN2TAAR1GAAALDH1A1
SCHEMBL21768197 0.79 TAAR1 (0.43) AKR1B1SMN1; SMN2TAAR1GAAALDH1A1
SCHEMBL29649325 0.79 TAAR1 (0.43) AKR1B1SMN1; SMN2TAAR1GAAALDH1A1
SCHEMBL24393849 0.78 IDO1 (0.41) ALDH1A1LMNAGABRA1GABRG2GABRB3
SCHEMBL11462339 0.77 TAAR1 (0.41) AKR1B1SMN1; SMN2TAAR1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022204150-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS BLUE OAK PHARMACEUTICALS, INC. (US) 2022-09-29 WO disclosed